Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.

NCT01785602 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: QAW039
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals